Navigation Links
Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
Date:11/3/2008

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

The experimental therapy is being offered to patients with chronic lymphocytic leukemia (CLL) whose cancer did not respond or was resistant to initial treatment or harbors a particular chromosomal abnormality called a 17p deletion. In most of these cases, the cancer has failed to respond to further conventional therapy.

In this clinical trial, patients will receive a vaccine of an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35) followed by three courses of rituximab, a monoclonal antibody, and the chemotherapy drugs fludarabine and cyclophosphamide (FCR). The trial is termed Phase I, meaning that it is aimed at testing the safety of the combination of repeat infusions of ISF35 and FCR, the latter being considered the standard and best possible CLL treatment.

"This approach activating immune cells followed by chemotherapy may lead to new strategies that could be applied to other cancers," said Januario E. Castro, M.D., assistant clinical professor of medicine at the UC San Diego School of Medicine and the Moores UCSD Cancer Center, who leads the work. The vaccine therapy approach makes it possible to target the cancer cells and activate the immune system by making the cancerous leukemia B cells more visible. The activated immune system can then find and eliminate the cancer cells.

CLL can be especially hard to treat. Though chemotherapy can beat back the disease initially, and patients may do well for years, the disease invariably returns, frequently resistant to further treatment. The American Cancer Society estimates that about 15,100 new cases of CLL will occur this year in the United States, with about 4,390 deaths from the disease.

"Standard strategies for CLL involve drugs and drug combinations that result in serious toxicities, little or no improvement in survival, and poor tolerance by the elderly," Castro said. "Almost all patients eventually experience disease relapse and become less responsive to therapy. Clearly we need novel therapeutic approaches for CLL, and ISF35 therapy represents such an innovation."

According to Castro, the latest study builds on previous trials completed at UCSD and M.D. Anderson Cancer Center in Houston. "Those trials showed remarkable results for ISF35 in patients with high-risk and treatment-resistant CLL," he said, particularly when combined with chemotherapy.

Castro said that ISF35 also has the "potential to treat a range of blood cancers including lymphomas and even certain types of breast and lung cancers and melanoma," adding that future clinical trials are being planned.


'/>"/>

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
2. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
3. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
4. HPV virus helps cervical and head and neck cancers resist treatment and grow and spread
5. New research finds markers for esophageal cancer before it develops
6. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
7. Samsung and Susan G. Komen for the Cure(R) Launch Historic Breast Cancer Alliance
8. Join the Pancreatic Cancer Action Network and Raise Your Voice in November for Pancreatic Cancer Awareness Month
9. Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments
10. Substance tackles skin cancer from 2 sides
11. Excess Weight Seems to Boost Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: